Pyrimidine metabolism enzyme

Pyrimidine metabolism enzymes are a group of enzymes responsible for the biosynthesis and degradation of pyrimidines—essential components for nucleic acid production. In the gastrointestinal tract, these include both the de novo synthetic pathway enzymes such as carbamoyl phosphate synthetase II, aspartate transcarbamoylase, dihydroorotase, dihydroorotate dehydrogenase, orotate phosphoribosyltransferase, and orotidine 5'-phosphate decarboxylase; as well as catabolic enzymes like cytosine deaminase and dihydropyrimidine dehydrogenase[1][3][7]. These pathways are crucial for maintaining nucleotide pools necessary for cell division and tissue regeneration in the gut. Several chemotherapeutic agents target these pathways—most notably 5-fluorouracil which inhibits thymidylate synthase—to disrupt cancer cell proliferation[2][4]. Genetic variability in some catabolic enzymes can lead to severe drug toxicity. The term "Pyrimidine metabolism enzymes in GI tract" is not a single molecular target but rather refers collectively to multiple distinct enzymatic proteins involved in this metabolic network; thus it is too broad to serve as a canonical therapeutic target name[1][3]. Key points indicating this entry is incorrect/too broad: The phrase "Pyrimidine metabolism enzymes in GI tract" does not refer to a single molecule but rather an entire class/family of related metabolic proteins. For structured data purposes each individual enzyme should be considered separately—for example "Dihydropyrimidine dehydrogenase", "Thymidylate synthase", etc.—rather than grouping all under one heading.[1][3]

Other names

Pyrimidine biosynthetic enzymePyrimidine catabolic enzymeEnzymes of pyrimidine metabolismDe novo pyrimidine synthesis enzymesPyrimidine salvage pathway enzymes

Inhibition of nucleotide synthesis (e.g., 5-FU inhibits thymidylate synthase)[2] Disruption of DNA/RNA synthesis in rapidly dividing cells